Mr. Gonzalez de Cosio is a Principal and co-founder of Pharmakon Advisors and manages the company’s portfolio. During the 14 years prior to founding Pharmakon Advisors, Mr. Gonzalez de Cosio held various positions in the structured finance divisions of Deutsche Bank and JP Morgan in New York, where he was responsible for structuring various forms of collateralised financings and derivatives for US and international clients, including several years covering clients in the life sciences industries. Mr. Gonzalez de Cosio’s prior experience also includes various positions in the investment banking division of Nomura Securities in New York, the leasing division of Socie ́te ́ Ge ́ne ́rale in Paris, and coordinating the issuance of external debt for the Mexican Ministry of Finance. Mr. Gonzalez de Cosio earned a B.A. degree (Summa Cum Laude) in Business Administration from the University of San Diego and an M.B.A. from INSEAD in Fontainebleau, France.

Mr. Legorreta is co-founder and Chief Executive Officer of Royalty Pharma and a Principal and co- founder of Pharmakon Advisors providing advisory oversight. Royalty Pharma was founded in 1996 and is a premier investor in pharmaceutical royalties. Prior to founding Royalty Pharma, Mr. Legorreta had a 10 year career in investment banking with Lazard Fre`res in Paris and New York. During his tenure at Lazard Fre`res, Mr. Legorreta co-founded two ‘‘proof of principle’’ funds that acquired royalties in Neupogen in 1993 and ReoPro in 1994. Mr. Legorreta is also a Director of Giuliani S.p.A. Mr. Legorreta is a member of the Association of University Technology Managers, the Licensing Executives Society, the Swiss Pharmaceutical Group, the Biotechnology Industry Organization, the Children’s Circle of Care and is a founding member of the Research Council of Boston’s Children’s Hospital. Mr. Legorreta earned a degree in Industrial Engineering from Universidad Iberoamericana in Mexico City, Mexico.

Mr. Friedman is a Principal of Pharmakon Advisors, having joined in 2011. Mr. Friedman has spent the past 22 years in various positions in the healthcare finance industry, most recently as the co-head of the US life sciences banking at Bank of America/Merill Lynch. He has worked very closely with both large cap and emerging pharmaceutical, biotech, specialty pharmaceutical, device and diagnostic companies, having advised on M&A transactions and raised equity and debt capital. Mr. Friedman’s prior experience also includes his 12 years at JPMorgan, including four years at JPMorgan Partners, and several years as the Head of M&A and Collaborations at Novartis AG based in Switzerland. Mr. Friedman earned a B.A. degree in English and History from Columbia College and an M.B.A. (Honours) in Finance and Accounting from Columbia Business School.